Key result
Clinical prediction model stratifies cancer-associated VTE recurrence risk into low versus high groups.
Why the study?
Whether treatment strategies for cancer-associated VTE should vary according to individual risk of VTE recurrence remains unknown.
Does a clinical prediction rule based on sex, primary tumor site, stage, and prior VTE accurately stratify the risk of recurrent VTE in patients with cancer-associated VTE?
Cohort (n=1,362)
Does a clinical prediction rule based on sex, primary tumor site, stage, and prior VTE accurately stratify the risk of recurrent VTE in patients with cancer-associated VTE?
Answers are grounded in this paper and cite their sources.
A novel 4-item clinical prediction rule can effectively stratify the risk of recurrent VTE in patients with cancer-associated VTE, which may help tailor long-term anticoagulation therapy.
BACKGROUND: Long-term low-molecular-weight heparin (LMWH) is the current standard for treatment of venous thromboembolism (VTE) in cancer patients. Whether treatment strategies should vary according to individual risk of VTE recurrence remains unknown. We performed a retrospective cohort study and a validation study in patients with cancer-associated VTE to derive a clinical prediction rule that stratifies VTE recurrence risk. METHODS AND RESULTS: The cohort study of 543 patients determined the model with the best classification performance included 4 independent predictors (sex, primary tumor site, stage, and prior VTE) with 100% sensitivity, a wide separation of recurrence rates, 98.1% negative predictive value, and a negative likelihood ratio of 0.16. In this model, the score sum ranged between -3 and 3 score points. Patients with a score ≤ 0 had low risk (≤ 4.5%) for recurrence and patients with a score >1 had a high risk (≥ 19%) for VTE recurrence. Subsequently, we applied and validated the rule in an independent set of 819 patients from 2 randomized, controlled trials comparing low-molecular-weight heparin to coumarin treatment in cancer patients. CONCLUSIONS: By identifying VTE recurrence risk in cancer patients with VTE, we may be able to tailor treatment, improving clinical outcomes while minimizing costs.
No takes yet. Share an insight, caveat, or question.
Louzada et al. (2012) conducted a cohort in Cancer-associated venous thromboembolism (VTE) (n=1,362). Clinical prediction rule (sex, primary tumor site, stage, and prior VTE) was evaluated on VTE recurrence risk. A clinical prediction rule using sex, tumor site, stage, and prior VTE successfully stratified cancer-associated VTE patients into low and high recurrence risk groups.
Synapse has enriched 10 related papers. Consider them for comparative context: